Omeprazole Liconsa (Omeprazole)

Omeprazole Liconsa is a proton‑pump inhibitor that acts on the gastric acid secretion pathway to treat several acid‑related disorders.

• Gastro‑oesophageal reflux disease (GERD): Improves heartburn and esophageal irritation by reducing stomach acid.
• Peptic ulcer disease: Promotes healing of gastric and duodenal ulcers through acid suppression.
• NSAID‑induced gastric ulcer: Protects the stomach lining by lowering acid exposure.
• Helicobacter pylori eradication (in combination therapy): Enhances the effectiveness of antibiotic regimens by creating a less acidic environment.
• Zollinger‑Ellison syndrome: Controls excessive gastric acid production associated with gastrin‑producing tumors.

• Omeprazole irreversibly binds to the H+/K+ ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By inhibiting this pump, it blocks the final step of acid secretion, leading to a sustained reduction in gastric acidity and allowing the gastrointestinal mucosa to heal.

Omeprazole may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: Mild to moderate headache reported in some patients.
• Diarrhea: Loose stools occurring during short‑term therapy.
• Nausea: Transient feeling of queasiness.
• Abdominal pain: Mild discomfort in the stomach area.
• Flatulence: Increased intestinal gas.
• Constipation: Reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: Severe colitis associated with antibiotic‑like disruption of gut flora.
• Hypomagnesemia: Low magnesium levels that may cause muscle cramps or cardiac arrhythmia.
• Acute interstitial nephritis: Inflammation of the kidney interstitium.
• Stevens‑Johnson syndrome: Rare severe skin reaction.
• Fracture risk: Potential increase in hip, wrist or spine fractures with long‑term use.

When prescribing Omeprazole Liconsa, clinicians should consider several safety aspects.

• Assess renal function: Adjust use in patients with severe renal impairment.
• Evaluate hepatic status: Use with caution in moderate to severe liver disease.
• Monitor long‑term therapy: Review need for continued treatment after 8‑12 weeks.
• Consider drug‑induced nutrient deficiencies: Monitor magnesium and vitamin B12 levels during prolonged use.
• Avoid in known hypersensitivity: Discontinue if allergic reaction occurs.
• Store at below 25°C: Keep in the original packaging, protect from moisture and light.

Omeprazole Liconsa can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid)

• Ketoconazole: Reduced absorption of the antifungal due to increased gastric pH.
• Atazanavir: Decreased plasma concentrations compromising antiviral efficacy.
• Clopidogrel: Potential reduction in antiplatelet activity.

Moderate Interactions (Monitor Closely)

• Warfarin: May enhance anticoagulant effect, requiring INR monitoring.
• Digoxin: Possible increase in serum levels.
• Methotrexate: May raise systemic exposure, especially at high doses.